A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 264 participants.
Also called NCT06933472
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 264 participants
- Sponsor
- Registry
-
NCT06933472
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, China
- Registry status
- Recruiting
Technical summary
Registry record NCT06933472. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-13 (actual); primary completion 2026-06-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
- Acronym
- RESPOND-2
- Condition
- Hyperphosphatemia
- Condition
- Chronic Kidney Disease, Receiving Dialysis
- Condition
- ESRD (End-Stage Renal Disease)
- Condition
- Dialysis
- Intervention (Drug)
- AP301
- Intervention (Drug)
- AP301 Low Dose
- Lead sponsor
- Alebund Pharmaceuticals
- Collaborator
- Fortrea
Record details
- Record id
cardio:ct-nct06933472- Content hash
3c03c48b9487d2f00bd4ce124aea53a6f6b997bf2edff0ca39cb189dc63a5012